Quarterly ResultMay 5, 2026, 04:09 PM
Tempus AI Q1 Revenue $348.1M, up 36.1%; Adjusted EBITDA ($2.8M)
AI Summary
Tempus AI reported strong first quarter 2026 financial results, with total revenue increasing 36.1% year-over-year to $348.1 million, driven by significant growth in both Diagnostics and Data and Applications segments. The company saw an 82.5% improvement in Adjusted EBITDA, reaching ($2.8 million), though net loss widened to ($125.9 million). Tempus AI also raised its full-year 2026 revenue guidance to $1.59 billion - $1.60 billion and reaffirmed its Adjusted EBITDA outlook of approximately $65 million, while announcing several new and expanded strategic collaborations.
Key Highlights
- Tempus AI Q1 2026 revenue increased 36.1% year-over-year to $348.1 million.
- Diagnostics revenue grew 34.7% to $261.1 million, driven by 28% Oncology volume growth.
- Data and Applications revenue rose 40.5% to $87.0 million, with Insights up 44.1%.
- Adjusted EBITDA improved significantly to ($2.8 million) from ($16.2 million) in Q1 2025.
- Net loss increased to ($125.9 million) from ($68.0 million) in Q1 2025.
- Cash and marketable securities stood at $643.8 million as of March 31, 2026.
- Full year 2026 revenue guidance raised to $1.59 billion - $1.60 billion, representing ~25% annual growth.
- Company expects full year 2026 Adjusted EBITDA of approximately $65 million.
- Established multi-year strategic collaborations with Merck and expanded with Gilead.
- Partnered with Northwestern Medicine and NYU Langone Health for genomic testing and research.